The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study.
 
Alberto F. Sobrero
Consulting or Advisory Role - Amgen; Bayer; BMS; Celgene; Hutchmed; Menarini; Merck Serono; MSD Oncology; Roche; Sanofi; SERVIER
Speakers' Bureau - amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; celgene; Lilly; Merck Serono; Roche; Sanofi; Takeda
Travel, Accommodations, Expenses - Bayer; Roche
 
Arvind Dasari
Consulting or Advisory Role - Crinetics Pharmaceuticals; Novartis; Personalis; Voluntis
Research Funding - Eisai; Guardant Health; Hutchison MediPharma; Merck
 
Sara Lonardi
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Incyte; Lilly; Merck Serono; Mirati Therapeutics; MSD; SERVIER
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)
 
Rocio Garcia-Carbonero
Honoraria - Advanced Accelerator Applications; Advanz Pharma; Amgen; AstraZeneca (I); Bayer; BMS; Boehringer Ingelheim (I); Gilead Sciences (I); Hutchmed; Ipsen; Lilly (I); Merck; Midatech Pharma; Mirati Therapeutics (I); MSD; Novartis; Pfizer (I); PharmaMar; Roche (I); Sanofi (I); Servier; Takeda (I)
Consulting or Advisory Role - HMP
Research Funding - BMS (Inst); MSD (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Merck; MSD; Roche
 
Elena Elez
Honoraria - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Roche; Sanofi/Aventis; SERVIER
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; Bristol Myers Squibb; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; SERVIER
Research Funding - Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); Genentech (Inst); HalioDx (Inst); Hutchison MediPharma (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Menarini (Inst); Merck (Inst); Merck Sharp&Dohme de España SA (Inst); Merus NV (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Serono; Roche; Sanofi; SERVIER
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Genomedia (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)
 
James C. Yao
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Chiasma; Crinetics Pharmaceuticals; Hutchison MediPharma; Ipsen
Research Funding - Advanced Accelerator Applications; Novartis
 
Pilar Garcia-Alfonso
Consulting or Advisory Role - Amgen; Merck Serono; Pierre Fabre; SERVIER
Speakers' Bureau - Amgen; Merck Serono; Pierre Fabre; Sanofi; SERVIER
 
Judit Kocsis
No Relationships to Disclose
 
Antonio Cubillo
No Relationships to Disclose
 
Andrea Sartore-Bianchi
Consulting or Advisory Role - Amgen; Bayer; Novartis; Sanofi; SERVIER
 
Taroh Satoh
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiihi-Sankyo; Lilly; Merck; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); IQVIA (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Yakult Honsha (Inst)
 
Violaine Randrian
Travel, Accommodations, Expenses - Amgen; Bayer; Merck
 
Jiri Tomasek
Honoraria - Amgen; Bristol-Myers Squibb; Merck; Pierre Fabre; SERVIER
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Pierre Fabre; SERVIER
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Merck; Pierre Fabre; SERVIER
Travel, Accommodations, Expenses - Merck; Novartis
 
Geoff Chong
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - AstraZeneca; Bayer; Bristol-Myers Squibb; HUTCHMED; Incyte; Isofol Medical; Merck Serono; Pharmacyclics; Regeneron
 
Zhao Yang
Employment - HUTCHMED
 
William R. Schelman
Employment - HUTCHMED
Stock and Other Ownership Interests - HUTCHMED; Lilly
 
Marek K. Kania
Employment - HUTCHMED
Leadership - HUTCHMED
Stock and Other Ownership Interests - HUTCHMED
 
Josep Tabernero
Stock and Other Ownership Interests - Oniria Therapeutics
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; HalioDx; Hutchison MediPharma; Ikena Oncology; Inspirna; IQvia; Lilly; Menarini; Merck Serono; Merus; Mirati Therapeutics; MSD; Neophore; Novartis; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology; Scorpion Therapeutics; Seagen; Servier; Sotio; Taiho Pharmaceutical; Tessa Therapeutics; TheraMyc
Other Relationship - Imedex/HMP; Medscape; MJH Life Sciences; Peerview; Physicans' Education Resource
 
Cathy Eng
Consulting or Advisory Role - Bayer Health; GlaxoSmithKline; HalioDx; Janssen Oncology; natera
Research Funding - Elevar Therapeutics (Inst); Hutchison China Meditech (Inst)
(OPTIONAL) Uncompensated Relationships - Merck (Inst); Pfizer (Inst)